All 1 tracked stories fall under one category: market-trends. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 8 runs above the beat's 5.9 for that window. Each story carries 2 original sources on average, compared with 3 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Mounjaro
All 1 tracked stories fall under one category: market-trends. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 8 runs above the beat's 5.9 for that window. Each story carries 2 original sources on average, compared with 3 for the broader beat in this window. We currently track 1 Healthcare story that mention Mounjaro, all published on March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Mounjaro. Shared-story counts are live from our verified record — not editorial picks.
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 diabetes trial, a result that matches or slightly trails the performance of its own blockbuster Mounjaro. While the glucose-lowering data is robust, the market's primary interest remains focused on the drug's potential for industry-leading weight loss and metabolic benefits.
